NASDAQ$LGVN

Longeveron Inc-A · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Reports awaiting report

Longeveron hasn't published Q4 2025 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q1 2026

    Revenue
    $398K
    EPS
    -$0.19
  • Year-ago · Q4 2024

    Q4 2024

    Revenue
    $773K
    EPS
    -$0.34
  • FY2025 consensus

    Analyst consensus

    Revenue
    $3.05M
    EPS
    -$1.49

Revenue & EPS history

Longeveron · Revenue · Quarterly

$398K

Q1 2026+4.5%vs Q1 2025
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Historical revenue by segment

Longeveron · $150K total across 1 segment · Q4 2023

  • Clinical Trial Revenue
    $150K—

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-5.1%

Avg return

Earnings day

-5.7%

Avg return

5 days after

+23.1%

Avg return

30 days after

35%

7 / 20 earnings

Positive

+10.0%

Q1 2022

Best reaction

-35.7%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.7%-11.0%—
Q4 2025-4.7%-0.7%+6.1%
Q3 2025-4.3%-7.3%-23.1%
Q1 2025-10.1%-9.4%-17.4%
Q4 2024-9.2%-5.3%+2.0%
Q3 2024-2.3%-8.8%-14.3%
Q2 2024-7.5%-11.3%-21.8%
Q1 2024+3.1%-1.5%+106.9%
Q4 2023+0.7%+0.0%-39.8%
Q3 2023-6.7%-0.5%+17.6%
Q2 2023-6.5%-12.0%-25.8%
Q1 2023-6.1%-11.9%-0.9%
Q4 2022-15.5%-17.5%-25.0%
Q3 2022+5.1%+2.6%-14.1%
Q2 2022+3.9%+1.3%-14.5%
Q1 2022+10.0%+16.2%-0.7%
Q4 2021-14.4%-7.1%+37.8%
Q3 2021-4.9%-15.6%+461.6%
Q2 2021-35.7%-32.9%-31.1%
Q1 2021+1.7%+17.9%+35.8%
Q3 2020———
Q2 2020———
Q1 2020———
Q4 2019———

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro